Results 31 to 40 of about 961,854 (252)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab [PDF]

Journal of Liver Cancer, 2023
Background/Aim Radiotherapy (RT) is an effective local treatment for hepatocellular carcinoma (HCC). However, whether additional RT is safe and effective in patients with advanced HCC receiving atezolizumab plus bevacizumab remains unclear.
Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park   +4 more
doaj   +1 more source

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Signal Transduction and Targeted Therapy, 2023
Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC.
Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Hui-Chuan Sun, Fei Liang, Yuan Ji, Yi Chen, Guo-Huan Yang, Jia-Cheng Lu, Xian-Long Meng, Xin-Ying Wang, Lei Sun, Ning-Ling Ge, Xiao-Wu Huang, Shuang-Jian Qiu, Xin-Rong Yang, Qiang Gao, Yi-Feng He, Yang Xu, Jian Sun, Zheng-Gang Ren, Jia Fan, Jian Zhou   +22 more
doaj   +1 more source

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2

Journal of Hematology & Oncology, 2016
Background Our previous study reported that microRNA-26a (miR-26a) inhibited tumor progression by inhibiting tumor angiogenesis and intratumoral macrophage infiltration in hepatocellular carcinoma (HCC). The direct roles of miR-26a on tumor cell invasion
De-Ning Ma, Zong-Tao Chai, Xiao-Dong Zhu, Ning Zhang, Di-Hua Zhan, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin, Yi-Ming Zhao, Wei-Ping Zhu, Man-Qing Cao, Dong-Mei Gao, Hui-Chuan Sun, Zhao-You Tang   +13 more
doaj   +1 more source

Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry [PDF]

Journal of Liver Cancer
Backgrounds/Aims Hepatocellular carcinoma (HCC) is the sixth most common cancer and second leading cause of cancer-related deaths in South Korea. This study evaluated the characteristics of Korean patients newly diagnosed with HCC in 2016-2018.
Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim   +16 more
doaj   +1 more source

An mALBI-Child–Pugh-based nomogram for predicting post-hepatectomy liver failure grade B–C in patients with huge hepatocellular carcinoma: a multi-institutional study

World Journal of Surgical Oncology, 2022
Objective Post-hepatectomy liver failure (PHLF) is a severe complication in patients with hepatocellular carcinoma (HCC) who underwent hepatectomy.
Ming-Hao Xu, Bin Xu, Chen-Hao Zhou, Zhong Xue, Zhao-Shuo Chen, Wen-Xin Xu, Cheng Huang, Xiao-Dong Zhu, Jian Zhou, Jia Fan, Hui-Chuan Sun, Ying-Hao Shen   +11 more
doaj   +1 more source

A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples

Diagnostics, 2021
Objectives: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant cancer. More than 70% of patients are diagnosed at an advanced stage. The aim of this study was to evaluate the diagnostic value of plasma miR-21, miR-122, and CA19-9, hoping to ...
Jie Hu, Yi-Ning Wang, Dan-Jun Song, Jin-Peng Tan, Ya Cao, Jia Fan, Zheng Wang, Jian Zhou   +7 more
doaj   +1 more source

Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma

Cancer Cell International, 2019
Background Oxaliplatin-based chemotherapy is widely used to treat hepatocellular carcinoma (HCC). Recent studies suggested that therapeutic resistance of tumors was affected by tumor microenvironment (TME).
Xiu-Tao Fu, Kang Song, Jian Zhou, Ying-Hong Shi, Wei-Ren Liu, Guo-Ming Shi, Qiang Gao, Xiao-Ying Wang, Zhen-Bin Ding, Jia Fan   +9 more
doaj   +1 more source

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study

Molecular Oncology, 2022
We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC).
Gui‐Qi Zhu, Wei‐Ren Liu, Zheng Tang, Wei‐Feng Qu, Yuan Fang, Xi‐Fei Jiang, Shu‐Shu Song, Han Wang, Chen‐Yang Tao, Pei‐Yun Zhou, Run Huang, Jun Gao, Hai‐Xiang Sun, Zhen‐Bin Ding, Yuan‐Fei Peng, Zhi Dai, Jian Zhou, Jia Fan, Ying‐Hong Shi   +18 more
doaj   +1 more source

Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study [PDF]

Journal of Liver Cancer
Backgrounds/Aims The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database from the Korean Health Insurance ...
Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi   +6 more
doaj   +1 more source

Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma

Molecular Cancer, 2020
Objective Natural killer (NK) cells play a critical role in the innate antitumor immune response. Recently, NK cell dysfunction has been verified in various malignant tumors, including hepatocellular carcinoma (HCC).
Peng-Fei Zhang, Chao Gao, Xiao-Yong Huang, Jia-Cheng Lu, Xiao-Jun Guo, Guo-Ming Shi, Jia-Bin Cai, Ai-Wu Ke   +7 more
doaj   +1 more source